Asahi Kasei Corporation 3407

TOKYO, September 29, 2026--Asahi Kasei Therapeutics, Veloxis Pharmaceuticals, Calliditas Therapeutics, and AiCuris will come together under the Asahi Kasei Therapeutics brand.

Asahi Kasei Corp (AHKSF) recently announced a total dividend of $0.14 per share, with the ex-dividend date set for 2026-09-29. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using data from GuruFocus, let us look into Asahi Kasei Corp's dividend performance and assess its sustainability for long-term value investors.

EVs, Fast Charging and Safer Energy Storage Drive Demand for Advanced Battery Separators, Spurring Ceramic-Coated, Ultra-Thin and Solid-State InnovationDublin, Sept. 25, 2026 (GLOBE NEWSWIRE) -- "Battery Separators Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. The global battery separators market was valued at USD 7.7 billion in 2025 and is projected to reach USD 19.1 billion by 2035, expanding at a compo

GLENVIEW, Ill., September 15, 2026--Asahi Kasei Bioprocess will unveil the VANTIJ® SU-VFC Benchtop at Bioprocess International East (BPI EAST) 2026.

TOKYO, September 08, 2026--Asahi Kasei Microdevices has announced that its CZ39 and CZ3K series have been adopted as in Microchip Technology's ML/AI-based AFD reference design.

Asahi Kasei (TSE:3407) is back in focus after the grand opening of its Hipore wet process lithium ion battery separator coating line in Charlotte, North Carolina. This marks a key step in its North American battery strategy. Recent moves in Asahi Kasei’s share price suggest investors are starting to factor in these new battery and electrolysis projects, with a 1-day share price return of 3.41% and a year-to-date share price return of 19.72% helping build momentum despite a softer 90-day...

Asahi Kasei (TSE:3407) opened a new Hipore wet-process lithium-ion battery separator coating line in North Carolina as part of its North American battery supply chain build-out. The company introduced a new lithium pre-doping technology aimed at high-voltage lithium-ion batteries, targeting higher energy density and lower costs. Asahi Kasei secured economic incentives to support expansion of its electrolysis facility in Japan, tied to hydrogen-related and chlor-alkali markets. The North...

Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, today announced that the first participant has been dosed in its Phase 2 clinical trial [NCT07290777] of pegrizeprument, a novel investigational maintenance immunosuppressive agent being studied for prevention of organ rejection in kidney transplant recipients.

TOKYO, August 26, 2026--Asahi Kasei held a grand opening ceremony for its new Hipore™ wet-process lithium-ion battery separator coating line in Charlotte, North Carolina.

TOKYO, August 20, 2026--Asahi Kasei has developed a novel pre-doping technology for high-voltage lithium-ion batteries (LIBs) with silicon-based anodes.

TOKYO, August 19, 2026--Asahi Kasei’s project to build new facilities for electrolysis equipment has been awarded key regional economic incentives.

Accelerating corporate net-zero commitments and tightening regulations on conventional chemical emissions highlighted by Invista’s ISCC PLUS mass-balance certification, Ascend Performance Materials’ low-carbon manufacturing expansions, Genomatica’s microbial fermentation process licensing, and strategic momentum across Asahi Kasei Corporation and Radici Group are driving rapid transition toward bio-based chemical intermediates. This comprehensive study delivers an in-depth analysis of production

TOKYO, July 15, 2026--Asahi Kasei Microdevices began mass production of the AK5816AIM, an AiM mmWave radar module.

TOKYO, July 07, 2026--Asahi Kasei has constructed a new slitting facility for SUNFORT™ dry film photoresist (DFR) at its manufacturing site in Tainan, Taiwan, on July 3.

TOKYO, June 25, 2026--Peptistar has integrated Asahi Kasei’s novel forward osmosis–membrane distillation (FO–MD) system into its facility for trial production of APIs.

Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA. Data presentations will include three posters highlighting real-world health economics and outcomes research, and a post-hoc ana

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Specialty Chemicals Market size & share revenue was valued at approximately USD 902 Billion in 2025 and is expected to reach USD 949 Billion in 2026 and is expected to reach around USD 1497 Billion by 2035, at a CAGR of 5.2% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Lanxess AG, Arkema S.A., Asahi